Tag: Eisai

Eisai to Voluntarily Withdraw BELVIQ®/BELVIQ XR® in the U.S.

Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being taken a...

Gilead Sciences and Eisai Agreed on Distribution and Co-Promotion of Filgotinib

gilead
Gilead Sciences, Inc. and Eisai Co., Ltd. announced that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigat...

BioArctic AB Announced Research Collaboration with Eisai

BioArctic AB announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration w...

Lenvima Accepted by NMPA for Additional Indication of Differentiated Thyroid Cancer

Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of C...

Eisai Launched Equfina® in Japan

Eisai Co., Ltd. announced that it has launched the Equfina® 50mg TABLETS (safinamide mesilate, “Equfina”) for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disea...

Eisai Agreed to Transfer Rights for Tazemetostat to Royalty Pharma

Eisai Co., Ltd. announced that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic...

Lenvima Sales in 1H2019 Doubled

Sales of Eisai's Lenvima more than double in the first half of 2019. Headline results for the first half: Revenue JPY 299.3 billion ($2.7 billion) -3.5% Profit JPY ...

Eisai Fycompa® Approved in China

Eisai Co., Ltd. announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa® (perampanel) from the China National Medical Products Admi...

Eisai and Merck Announced Final Results from Study Evaluating LENVIMA plus KEYTRUDA

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 e...

Numab and Eisai Agreed to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer

drug development
Numab Therapeutics AG announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapi...

Eisai and Nichi-Iko Entered Collaboration Agreement for Generics in China

generic
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical announced that they have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. The Chinese pharmaceutic...

Eisai and Tokio Marine & Nichido Fire Insurance Announced Business Alliance Agreement

Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced that the companies have entered into a business alliance agreement for co-existence and prevention of dementia. Und...

Eisai and Meiji Seika Announced Manufacturing and Marketing Approval in Japan for Equfina® TABLETS

japan
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced the manufacturing and marketing approval in Japan for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s di...

Eisai Pharma India and Mylan Agreed to Promote TECERIS® in India

Eisai Co., Ltd. announced that Eisai’s subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the secon...

Eisai and Biogen Decided to Discontinue Clinical Studies on Oral BACE Inhibitor

Eisai Co., Ltd. and Biogen Inc. announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbe...

Eisai Lost Salagen® Case Against SpePharm AG in the U.S.

SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisa...